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Introduction, epidemiology, and risk factors
Over the past 50 years, the incidence of melanoma in most
developed countries has risen faster than any other cancer
type. Once a rare cancer, incidence rose dramatically between
the 1930s and 1970 (?10%/year, doubling every ten years),
slowing to its present rate of ?5%/year over the last 30 years
(Figure 1) (Berwick and Halpern, 1997; Oliveria et al., 2001).
Mortality rates have also risen substantially, although at a slow-
er rate. In the U.S., 1 in 82 women and 1 in 58 men will develop
melanoma. Unlike the majority of cancers, melanoma incidence
is not strongly dependent on age, and melanoma is one of the
most common causes of cancer and cancer deaths between
the ages of 20–35. Thus, by afflicting young and middle-aged
adults, the socioeconomic and psychological impact is great.
Melanoma provides one of the best examples of how genet-
ics and environment interact in the pathogenesis of cancer.
Incidence is strongly affected by race and geographic location
(Balch et al., 2002). Melanoma is predominantly a disease of
populations with lighter pigmentation (i.e., Caucasians) and inci-
dence is 5- to 20-fold lower in populations with darker skin color
(e.g., Africans, East Asians, Hispanics) (see Figure 1). Within
Caucasian populations, incidence is influenced by proximity to
the equator, suggesting a link to solar exposure. For instance,
melanoma incidence in the southern U.S. is two to three times
higher than the northern U.S. Studies of migrants further empha-
size the role of environment, based on retained high-risk when
migrants moved from high incidence to lower incidence areas.
Melanocytic nevi (moles), benign clusters of melanocytes,
have drawn special attention as potential precursor lesions.
However, Caucasians have an average of 15–35 benign com-
mon nevi per person, and the risk of an individual benign com-
mon nevus becoming melanoma is extremely small. In addition,
only ?10%–20% of primary melanomas are associated with
nevi, suggesting that the large majority of primary melanomas
do not arise from nevi. On the other hand, so-called “atypical
nevi” are a marker for increased risk for melanoma. For
instance, persons with >100 flagrant atypical nevi and a family
history of melanoma have a very high probability (lifetime risks
approaching 100%) of developing melanoma. However, none of
the clinical diagnostic criteria for atypical nevi are precise or
highly reproducible. Atypical nevi are prevalent in Caucasian
populations (as high as 18% of individuals). There is a desper-
ate need for more reliable, molecularly defined markers for
these “atypical” lesions. An undisputed precursor lesion is lenti-
go maligna, a benign pigmented lesion occurring on heavily
sun-exposed skin usually in elderly individuals. It is estimated
that 5%–30% of lentigo maligna lesions progress to invasive
lentigo maligna melanoma, linking chronic sun exposure to this
special type of melanoma.
Genetic factors play a dominant role in risk for melanoma
(Polsky et al., 2001b). In addition to skin pigmentation, other her-
itable risk factors include family history of melanoma, density
and type of nevi, and propensity to sunburn but not tan. With
regard to environmental factors, several lines of epidemiologic
evidence point to an increased relative risk related to sun expo-
sure: (1) higher incidence at lower latitudes for Caucasian popu-
lations, and (2) occurrence of melanoma most frequently on skin
sites that are exposed to the sun during recreation (e.g., not pro-
tected by bathing suits). A confounding observation is that per-
sons who work outdoors, with the heaviest sun exposure, have a
lower incidence of melanoma than white-collar workers and pro-
fessionals who work indoors. One proposed explanation is the
“intermittent sun exposure” hypothesis, suggesting that the risk
comes from exposure of untanned skin to relatively short bursts
of high intensity sun (e.g., sunburns during winter vacation in
Florida) (Houghton and Viola, 1981). The action spectra of solar
radiation implicated in melanoma are not clear—there are argu-
ments for both the mutagenic UV-B radiation (sunburn and tan-
ning wavelengths) and the proinflammatory, melanocyte activa-
tion effects of UV-A (tanning wavelengths) (Kripke, 1991; Wang
et al., 2001). In addition, UV radiation induces immune suppres-
sion in the skin, theoretically interfering with immunological
mechanisms of cancer surveillance (Kripke, 1991). Perhaps the
clearest evidence for a relationship between UV exposure and
melanoma comes from a genetic experiment of nature, a rare set
of heritable diseases called xeroderma pigmentosum that are
characterized by molecular defects in nucleotide excision repair
of UV-B-induced DNA damage. Patients with xeroderma pig-
mentosum developed large numbers of nonmelanomas skin
cancers by early adulthood (Lynch et al., 1967), and a subset are
at extraordinarily high risk (>1000-fold) for melanoma. However,
the relationship of sun exposure to melanoma is complex and
mechanisms are uncertain.
Natural history and precursor lesions
Melanoma arises from normal pigment cells, the neural crest-
derived melanocytes, located on the basement membrane of
epithelial surfaces (Figure 2). A major function of melanocytes
is the synthesis, storage, and transfer of melanin pigments to
surrounding epithelial cells. Melanin in melanocytes is synthe-
sized in special endocytic vesicles called melanosomes
(Vijayasaradhi et al., 1995). Primary melanoma cells generally
retain these differentiation functions to make and store pigment
in melanosomes. The presence of pigment, melanosome-spe-
cific proteins by immune staining, and melanosomes by elec-
tron microscopy can be used diagnostically to distinguish
melanoma from other types of cancer. Most melanomas arise
on the skin (>90%), particularly sun-exposed sites on the limbs,
trunk, and face. Notably, melanomas in persons with dark skin
arise at a much higher frequency in non-sun exposed sites,
including mucous membranes, nailbeds, palms, and soles of
feet. Approximately 3%–5% of melanomas arise from
melanocytes in the uveal tract of the eye (not to be confused
with retinal pigmented epithelial cells), and rarely from noncuta-
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neous epithelial surfaces including mucous membranes of the
sinuses and oropharynx, esophagus, rectum, and vagina.
Approximately 5% of melanoma cases first appear as metastat-
ic lesions with no known primary site. In most cases, these
probably represent complete regression of an initial cutaneous
primary lesion (through perhaps immunological or other host
mechanisms), with no effect of melanoma regression at the pri-
mary site on the relatively poor prognosis of metastases,
emphasizing differences in the biology of primary versus
metastatic lesions. Several lines of evidence have clearly
demonstrated that the immune system can recognize
melanoma cells. In fact, much of our knowledge of cancer
immunity in humans comes from studies of melanoma
(Houghton et al., 2001). Immune therapies including interferons
and interleukin-2 are standard treatments for advanced
melanoma, although not very effective (Balch et al., 2002).
Diagnosis, staging, and conventional therapy
The large majority of persons diagnosed with melanoma are
cured (>85%) due to diagnosis at early stages of tumor progres-
sion. On the other hand, melanoma can be highly malignant,
metastasizing to almost any organ in the body; melanoma diag-
nosis at later stages of tumor progression is associated with a
poor prognosis.Typical clinical characteristics of melanoma skin
lesions include asymmetry, irregularity of borders, variability in
color, and diameter >6 mm (the so-called “ABCD’s” of
melanoma). However, even the most experienced clinicians
have difficulty diagnosing pigmented lesions correctly, and clini-
cal accuracy of diagnosis rarely exceeds 60%. Pathological
examination must be used to establish a diagnosis.
Invasion and metastases are the two cardinal characteristics
of cancer, and form the basis for pathologic diagnosis and stag-
ing melanoma. The well-defined progression of malignant trans-
formation from normal melanocytes to metastatic melanomas
provides an excellent model for malignant transformation, inva-
sion and metastases (Figure 2). Primary melanoma progresses
generally through two phases (Figure 2): (1) the radial growth
phase characterized by horizontal spreading of transformed
melanocytic cells within the epidermis, and small nests of inva-
sive cells limited to the upper part of the dermis, and (2) vertical
growth phase characterized by invasion of melanoma cells into
the deeper dermis and underlying subcutaneous tissues.
Generally only vertical phase melanoma lesions are associated
with metastasis, while pure radial growth phase melanomas
almost never metastasize. These observations suggest that
invasion is required for metastasis, and in fact outcome is deter-
mined by the depth of invasion, the predominant prognostic fac-
tor. Staging of primary melanomas is based on the depth of
(Clark et al., 1969) invasion into the dermis, using either Clark’s
method (based on anatomic skin markers) or Breslow’s method
(direct measurement of depth of invasion from the epidermis).
The TNM classification is used to determine stage (T, primary
tumor; N, regional lymph nodes; M, metastases). In situ (stage 0)
melanomas are noninvasive, and have not broken the integrity of
the epidermal basement membrane (these lesions are not
included in melanoma statistics). Stage I (generally ≤2.0 mm
depth) and stage II (>2.0 mm depth) melanomas are localized
primary tumors and are treated by surgical excision. Stage III
melanoma is characterized by regional spread through lymphat-
ic vessels, and is treated by surgery with or without adjuvant
therapy using interferon-α2b. In stage IV melanoma, distant
metastases are disseminated through hematogenous spread. In
addition to surgery and radiation therapy, systemic therapy
(chemotherapy and immunotherapy) is used, but induces com-
plete remissions in only a small proportion of patients.
Key genes and pathways involved in sporadic and 
familial melanoma
Loss of cell cycle regulation
Alterations of chromosomes 1, 6, 7, and 10 are prevalent in
melanomas, but appear to be acquired late in tumor progression.
Other genetic observations have implicated alterations in the Rb
pathway for cell cycle regulation as an early step in the pathogen-
esis of melanoma. Frequent deletions in the 9p21 region in pri-
mary melanoma lesions as well as in melanoma cell lines led to
the eventual identification of p16INK4A (within the CDKN2A/
MTS1 locus) as the candidate tumor suppressor by linkage
analysis (Cannon-Albright et al., 1992; Fountain et al., 1992).
Mutations in the INK4A region account for only ?20% of familial
melanoma kindreds, implying that other genes are responsible in
the majority of familial melanomas. Although the CDKN2A locus
also encodes p14ARF (which influences cell cycle through the
p53 pathway rather than the Rb pathway), evidence supporting a
role of ARF in melanoma is currently lacking. Penetrance of
CDKN2A germline mutations in melanoma susceptibility in pre-
dominantly Caucasian populations varies according to geograph-
ic location—for instance, 0.58 in Europe and 0.91 in Australia by
age 80 (Bishop et al., 2002). In three melanoma families a CDK4
mutation (R24C) has been identified, but such mutations are rare
in melanoma family kindreds (Zuo et al., 1996). p16INK4A inhibits
the G1-S transition by blocking the activity of cyclin-dependent
kinases 4 and 6 (CDK4 and CDK6) that regulate early phosphor-
ylation of the Rb protein. Binding of p16INK4A to CDK4 is blocked
by the R24C mutation, and knock-in mice expressing a mutant
CDK4 R24C allele develop melanomas, establishing a role for the
Rb pathway (Sotillo et al., 2001). Somatic mutations in p16INK4A
are relatively uncommon in sporadic (nonfamilial) melanomas
(ranging from 0%–28%). Epigenetic inactivation of p16INK4A via
methylation of the promoter region has been observed in a small
proportion of cases. In a preliminary study upregulation of Id-1, a
transcriptional repressor of p16INK4A, has been detected in
Figure 1. Age-adjusted incidence rates in the United States, by race,
19731999, from the SEER database (http://www.seer.cancer.gov)
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early melanomas, providing an alternative mechanism to silence
p16INK4A (Polsky et al., 2001c). Interestingly, amplification of
cyclin D1 has been seen, but only in melanomas occurring on rel-
atively sun protected, acral (hands, feet) surfaces (Sauter et al.,
2002). Alterations of the p53 tumor suppressor pathway remain
poorly defined. Unlike many other common forms of cancer, p53
mutations are infrequent in melanomas. However, overexpres-
sion of the p53 inhibitor HDM2 is found in early melanomas, sug-
gesting concomitant dysregulation of the p53 pathway (Polsky et
al., 2001a). In support of a potential role for the p53 pathway, mice
expressing mutant ras alleles in a p53-deficient background
develop melanomas (Bardeesy et al., 2001). In metastatic
melanomas, inactivation of APAF-1, an effector of apoptosis
downstream of p53, is common and provides one explanation for
the resistance of melanoma to cytotoxic drug therapy (Soengas
et al., 2001).
Activation through the Ras pathway
Although mutations in RAS family genes in melanoma specimens
are uncommon (<10%), data from mouse models support the
role of this important pathway in tumorigenesis (Chin et al., 1999;
Bardeesy et al., 2000). Overexpression of the mutant Ha-Ras
oncoprotein has been shown to induce malignant transformation
of normal human melanocytes (Albino et al., 1992). Furthermore,
transgenic mice induced to express mutant Ha-Ras in cutaneous
melanocytes developed invasive melanomas when placed on a
CDKN2-deficient background although mutant ras alone was
insufficient to induce full transformation (Chin et al., 1999).
Interestingly, maintenance of growing tumors depended on con-
tinued expression of mutant Ha-Ras. Experimental models have
demonstrated that signaling via the bFGF receptor, upstream of
ras, contributes to melanoma tumorigenesis. Recently, a report
using human material suggested that activating mutations in
BRAF are very frequent in melanomas, detected in 59% of
melanoma cell lines and 6 of 9
melanoma specimens (Davies et al.,
2002). BRAF encodes a cytoplasmic ser-
ine/threonine kinase in the RAS pathway
(RAS→RAF→MEK→ERK→MAP kinase)
that is regulated by RAS binding. If con-
firmed in a broader panel of melanoma
specimens (including primary lesions),
BRAF would become a legitimate target
for experimental therapy of melanoma.
Another report suggested that overex-
pression of RhoC, a member of the Rho
family of GTP-hydrolyzing proteins, was important in the
switch from localized melanoma to metastatic disease (Clark
et al., 2000). These reports have provided evidence in human
material that alterations of the Ras pathway are important in
human melanoma.
Missing fingerprints for UV mutations
UV-B induces cyclobutane pyrimidine dimers, primarily thymi-
dine dinucleotides. Lesions not repaired by nucleotide excision
repair can lead to GC→AT transitions, leaving a mutagenic fin-
gerprint. In nonmelanoma skin cancers, mutations with a UV-B
signature are prevalent in the tumor suppressor gene p53. UV
signature mutations in melanoma specimens have not been
identified with any frequency in Ink4a or BRAF. These observa-
tions have provided little evidence for mutagenic effects of UV
radiation in the pathogenesis of melanoma. On the other hand,
the epidemiologic evidence for a role for solar exposure in
Caucasian populations is compelling. Furthermore, in an exper-
imental model, sunburn UV-B irradiation of neonatal mice
expressing hepatocyte growth factor from a transgene induced
a marked increase in melanocytic lesions (including those char-
acteristic of in situ melanomas, a potential precursor lesion of
invasive melanoma) compared to irradiated older mice (Noonan
et al., 2001). It is possible that other UV irradiation during child-
hood/adolescence is important and that target genes are waiting
to be discovered, but one must begin to think more seriously
about nonmutagenic mechanisms such as immune suppression,
UV induction of melanocyte growth factors by inflammatory cells
or damaged keratinocytes, or UV production of mutagenic oxida-
tive radicals during inflammation or melanogenesis.
Strategies for experimental therapies
Because systemic therapies for advanced melanoma are mar-
ginally effective, experimental therapies are an option for
Figure 2. Primary melanoma arises from
melanocytes
A vertical section of skin is illustrated, including
epidermis (level I at the left margin), dermis
(levels IIIV) and subcutaneous tissue (level V).
A: Column shows normal melanocytes arra-
nged individually at the epidermal-dermal
junction or in small organized clusters of benign
nevus. B: Proliferation of atypical melanocytes,
characteristic of atypical nevi. C: An early
melanoma in radial growth phase. D: An
advanced, invasive melanoma in vertical
growth phase. Depth of invasion, determined
by Clarks level and Breslow thickness, is the
major determinant of prognosis. A model of
biologic changes corresponding stages of
melanoma progression is presented at the top
of the figure. Reprinted from Polsky et al.
(2001b) with permission of Elsevier Science.
278 CANCER CELL : OCTOBER 2002
F O C U S
patients with advanced disease if they are eligible for protocols.
To date, the search for active therapies against melanoma has
been largely empiric. However, as pathways in melanoma
pathogenesis are revealed, new opportunities for targeted ther-
apies are appearing. The recent success of the kinase inhibitor
STI-571 in treating chronic myelogenous leukemia provides a
rationale for targeting appropriate tyrosine and serine/threonine
kinases in melanoma. These include drugs that target receptor
tyrosine kinases (e.g., FGF receptor) and molecules in the ras
pathway, including MAP kinase inhibitors, farnesyl transferase
inhibitors, and ansamycins (which destabilize folding of kinases
in the endoplasmic reticulum). Melanoma cells resist apoptosis,
particularly mediated through the mitochondrial pathway. One
mechanism involves deficiencies in Apaf-1, through deletion of
one allele and inactivation of the other allele by methylation.
Apaf-1 methylation can be inhibited by 5-azacytidine, reverting
resistance to apoptosis through the p53 pathway (Soengas et
al., 2001). These observations suggest that demethylating
agents could be combined with cytotoxic drugs to overcome
resistance. Other antiapoptotic molecules expressed in
melanoma include bcl-2, survivin, and livin. Antisense strategy
against bcl-2 in combination with chemotherapy is in clinical tri-
als.The immune system of melanoma patients can recognize
melanocyte-specific proteins, particularly melanosome proteins
and certain proteins expressed in germ cells that are extin-
guished in somatic cells but reexpressed in melanomas (some-
times called cancer-testes antigens). These molecules are tar-
gets for active immunotherapy (therapeutic vaccination).
Future challenges
Much remains to be learned about the pathogenesis of
melanoma. How do different receptors and signaling pathways
regulate uncontrolled growth, invasion, and metastases? What
is the role of solar exposure in the etiology of melanoma? As
genetics and cell biology reveal pathways and key molecules,
new targets for prevention and therapy will appear. Mouse mod-
els that recapitulate human melanoma and the relevant path-
ways should allow better preclinical models for screening and
developing new classes of therapeutic agents.
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